General Information of Drug Transporter (DT)
DT ID	DTD0057 Transporter Info
Gene Name	ABCC11
Protein Name	Multidrug resistance-associated protein 8
Gene ID	85320
UniProt ID	Q96J66
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs7194667
Site of GPD	chr16:48208987 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>G
Minor Allele Frequency	G=0.0421/211 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	Drug Info	Neoplasm	Correlated with the increased leukopenia risk in patients (compare with Genotype TT)		[ 1]
Fluorouracil	N.A.	Leukopenia	Genotypes GG + GT are associated with increased risk of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.		[ 1]
Fluorouracil	N.A.	Neoplasms	Genotypes GG + GT are associated with increased risk of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Fluorouracil	N.A.	Leukopenia	Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.		[ 1]
Fluorouracil	N.A.	Neoplasms	Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.		[ 1]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Fluorouracil	N.A.	Leukopenia	Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.		[ 1]
Fluorouracil	N.A.	Neoplasms	Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Fluorouracil	N.A.	Leukopenia	Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.		[ 1]
Fluorouracil	N.A.	Neoplasms	Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.		[ 1]
Genetic Polymorphism	rs17822471
Site of GPD	chr16:48208468 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9740/1927 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Leukopenia	Genotypes AA + AG is associated with increased risk of Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.		[ 2]
Fluorouracil	N.A.	Leukopenia	Genotypes AA + AG is associated with increased risk of Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.		[ 2]
Genetic Polymorphism	rs17822931
Site of GPD	chr16:48224287 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.7160/1416 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Capecitabine	N.A.	Drug Toxicity	Allele C is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.		[ 2]
Capecitabine	N.A.	Leukopenia	Allele C is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.		[ 2]
Fluorouracil	N.A.	Drug Toxicity	Allele C is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.		[ 2]
Fluorouracil	N.A.	Leukopenia	Allele C is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.		[ 2]
Genetic Polymorphism	rs8056100
Site of GPD	chr16:48226719 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.8810/1743 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Capecitabine	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele G.		[ 2]
Capecitabine	N.A.	Leukopenia	Allele A is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele G.		[ 2]
Fluorouracil	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele G.		[ 2]
Fluorouracil	N.A.	Leukopenia	Allele A is not associated with risk of Drug Toxicity or Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele G.		[ 2]
References
1	ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Pharmacogenomics. 2013 Sep;14(12):1433-48.
2	The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J. 2017 Jul;17(4):319-324.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.